Autologous melanoma-associated antigens (MAA) (MAA)

Autologous melanoma-associated antigens (MAAs) are a heterogeneous group of proteins expressed by melanoma cells that serve as the primary targets for personalized immunotherapy. These antigens include lineage-specific differentiation antigens (such as MART-1, gp100, and tyrosinase), cancer-testis antigens (like MAGE-A and NY-ESO-1), and unique neoantigens arising from somatic mutations (PMID: 22553348). In therapeutic applications, these antigens are presented by patient-specific Human Leukocyte Antigen (HLA) molecules on the surface of dendritic cells to prime the immune system. This interaction facilitates the activation and clonal expansion of CD8+ cytotoxic T cells and CD4+ helper T cells, which then circulate and recognize the same peptide-HLA complexes on the surface of tumor cells (PMID: 22918331). The resulting immune response leads to the targeted destruction of melanoma cells while ideally sparing normal tissues, although cross-reactivity with healthy melanocytes can occur. This approach is central to the development of personalized cancer vaccines and adoptive cell therapies aimed at overcoming the immunosuppressive tumor microenvironment (PMID: 28700575).

Other names

Melanoma-associated antigensTumor-associated antigensTAAMelanoma neoantigensPatient-specific tumor antigensMHC-peptide complexes

Induction of a tumor-specific immune response through the presentation of autologous melanoma antigens by HLA molecules on dendritic cells, leading to the activation and expansion of T cells that recognize and lyse tumor cells expressing those same antigens.